Phenaglycodol

Phenaglycodol

SCHEMBL259155

CC(C)(O)C(C)(O)c1ccc(Cl)cc1

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
TSHR P16473 1/20 0.52
MAPK1 P28482 1/20 0.52
HIF1A Q16665 1/20 0.52
NPSR1 Q6W5P4 2/20 0.48
CYP19A1 P11511 4/20 0.45
POLB P06746 2/20 0.44
BCL2 P10415 1/20 0.41
HSD11B1 P28845 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40
CYP2A6 P11509 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenaglycodol SCHEMBL329242 1.00 MEN1 (0.65) MEN1KMT2ATSHRMAPK1HIF1A
SCHEMBL17826 0.81 MEN1 (0.60) MEN1KMT2ATSHRMAPK1HIF1A
SCHEMBL1016971 0.79 KMT2A (0.71) MEN1KMT2ATSHRMAPK1HIF1A
SCHEMBL4297794 0.79 MEN1 (0.71) MEN1KMT2ATSHRMAPK1HIF1A
SCHEMBL26402 0.79 MEN1 (1.00) MEN1KMT2ATSHRMAPK1HIF1A
SCHEMBL18383532 0.77 TSHR (0.55) MEN1KMT2ATSHRNPSR1CYP19A1
SCHEMBL8743247 0.77 KMT2A (0.68) MEN1KMT2ATSHRMAPK1HIF1A
SCHEMBL2860836 0.75 TSHR (0.74) MEN1KMT2ATSHRMAPK1HIF1A
SCHEMBL3855932 0.75 MEN1 (0.65) MEN1KMT2ATSHRMAPK1HIF1A
SCHEMBL29092067 0.75 MEN1 (0.65) MEN1KMT2ATSHRMAPK1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1932 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4583410-A2 BIAS CIRCUIT FOR A DIGITAL-TO-ANALOG CONVERTER Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) 2025-07-09 EP claimed
US-20250202497-A1 BIAS CIRCUIT FOR A DIGITAL-TO-ANALOGUE CONVERTER COMMISSARIAT A L’ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2025-06-19 US claimed
CN-119722345-A High-rise building engineering insurance rate is decided based on construction risk evaluation 五邑大学 2025-03-28 CN claimed
CN-114372606-B EV (electric vehicle) aggregator short-time scheduling and response excitation method considering road traffic model 上海电力大学 2024-11-15 CN claimed
CN-114386270-B Multi-objective optimized array pattern synthesis method based on improved genetic algorithm 中国电子科技集团公司第五十四研究所 2024-10-29 CN claimed
CN-221153789-U Reverse suction preventing structure for spray head of steam water boiler 青岛吉之美商用设备有限公司 2024-06-18 CN claimed
CN-116628411-B High-precision flow online monitoring intelligent method based on full-sense fusion 长江水利委员会水文局 2024-05-17 CN claimed
CN-117726418-A Renewable energy source digestion method based on game model 郑州轻工业大学 2024-03-19 CN claimed
EP-4031714-B1 ROAD GUARDRAIL WITH MOTORCYCLIST-PROTECTION BARRIER MARGARITELLI FERROVIARIA S P A (IT) 2024-03-06 EP claimed
CN-219618776-U Thermal printing paper with transparent heat-conducting protective layer for clinical care of hospital 湖南金海医疗器械有限公司 2023-09-01 CN claimed
US-20020014092-A1 Method of manufacturing optical glass element, and optical glass element manufactured using the method NIPPON SHEET GLASS CO., LTD (JP) 2002-02-07 US claimed
CN-1329258-A Method for manufacturing optical glass element and optical glass element made by said method NIPPON SHEET GLASS CO LTD (JP) 2002-01-02 CN claimed
US-20010006962-A1 FATTY ACID DERIVATIVES NORSK HYDRO ASA (NO) 2001-07-05 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0977725-A1 NEW FATTY ACID DERIVATIVES NORSK HYDRO ASA (NO) 2000-02-09 EP claimed
WO-1998032718-A1 NEW FATTY ACID DERIVATIVES NORSK HYDRO ASA (NO) 1998-07-30 WO claimed
US-5023088-A Drug delivery dispenser ALZA CORPORATION (US) 1991-06-11 US claimed
EP-0359147-A2 Novel fluorine-containing non-crystalline copolymer DAIKIN INDUSTRIES, LIMITED (JP) 1990-03-21 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010006962-A1 FATTY ACID DERIVATIVES HADH, NR1H2, NR1H3 MEN1 4825/4885KMT2A 2289/4885TSHR 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.